April 11, 2019
WELLESLEY, Mass., April 11, 2019–The increasing prevalence of blood-borne infectious diseases and the introduction of novel technologies for sensitive and high-throughput detection methods are factors that help boost the blood screening and typing market, according to the latest report by BCC Research, “Blood Screening and Typing: Global Markets.”
The industry expects to see a compound annual growth rate (CAGR) of 5.0% through 2023, when it could be worth $9.9 billion, according to the report
Major players in the market include Abbott Molecular (ABT), Roche Diagnostics (ROG), Becton, Dickinson and Company (BDX), bioMérieux (BIM), and Danaher (DHR).
Research Highlights
“Across the globe, more than 112 million units of blood are donated annually, according to WHO, of which over 50% comes from high-income countries. However, donation growth is declining due to increase in surgical methodologies that create scope limiting the use of blood losses associated with surgeries,” notes the report’s authors.
Market Restraints Include Government Policies, Price Pressures
Though generally positive, there are several factors which are working to restrain the market, the report notes. Chief among those are government policies, led by a 2.3% medical device tax in the U.S. Meanwhile, intense competition in segments like the point-of-care testing market means manufacturers have encountered strong pricing pressure.
Editors/reporters requesting analyst interviews should contact Sarah Greenberg at press@bccresearch.com.
Blood Screening and Typing: Global Markets( HLC224A )
Publish Date: Mar 2019
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.